Engineered Adoptive T-Cell Therapies for Breast Cancer: Current Progress, Challenges, and Potential

Authors

Diego F Chamorro
Lauren K Somes
Valentina Hoyos

Publication Date

12-26-2023

Journal

Cancers

DOI

10.3390/cancers16010124

PMID

38201551

PMCID

PMC10778447

PubMedCentral® Posted Date

12-26-2023

PubMedCentral® Full Text Version

Post-print

Published Open-Access

yes

Keywords

breast cancer, immunotherapy, CAR T, TCR T, clinical trials

Abstract

Breast cancer remains a significant health challenge, and novel treatment approaches are critically needed. This review presents an in-depth analysis of engineered adoptive T-cell therapies (E-ACTs), an innovative frontier in cancer immunotherapy, focusing on their application in breast cancer. We explore the evolving landscape of chimeric antigen receptor (CAR) and T-cell receptor (TCR) T-cell therapies, highlighting their potential and challenges in targeting breast cancer. The review addresses key obstacles such as target antigen selection, the complex breast cancer tumor microenvironment, and the persistence of engineered T-cells. We discuss the advances in overcoming these barriers, including strategies to enhance T-cell efficacy. Finally, our comprehensive analysis of the current clinical trials in this area provides insights into the future possibilities and directions of E-ACTs in breast cancer treatment.

Comments

Associated Data